Latest California Healthline Stories
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
Orphan Drugs Interactive Database
Check out all the drugs the FDA has approved to treat rare diseases. You can search by brand name, or by disease, and see familiar names that were first sold on the mass market or all the drugs that won FDA approval to treat more than one rare disease.
GOP Vows To Defund Planned Parenthood. Reality Makes That Hard.
Ending federal support of the group that helps supply women’s reproductive health care could complicate health law overhaul efforts.
Follow the twists and turns of the orphan drug industry over the past three decades.
Video: Former U.S. Rep. Henry Waxman Shares Deep Concerns About Orphan Drugs
The former Congressman championed the Orphan Drug Act decades ago but now he fears it’s being manipulated to make money.
Top Price Contributor Allegedly Leaned On Employees To Support PAC
President-elect Donald Trump’s Cabinet pick Tom Price “assisted” a company and campaign donor who tapped executives with an urgent request to donate.
Crucial California HIV Program In Disarray After Contract Switch
Patients who depend on the state-run AIDS Drug Assistance Program are having trouble getting medical appointments and life-saving medications.
Mobile Team Offers Comfort Care To Homeless At Life’s End
A Seattle program pioneers palliative care that reaches dying patients on streets and in shelters.
Even In Trump Country, Rural Hospitals Brace For Damage From Health Law’s Repeal
The Affordable Care Act, which President-elect Donald Trump has vowed to repeal, threw a number of life-savers to rural hospitals, which are vital but financially troubled centers. And its full repeal, without a comparable and viable replacement, could signal their death knell.
Trump’s HHS Nominee Got A Sweetheart Deal From A Foreign Biotech Firm
Price and another influential GOP congressman got a discounted deal as an Australian firm seeking federal approval sought “sophisticated U.S. investors.”